ESR1 and breast cancer: ASCO/CAP guidelines [26] recommend defining ER-low positivity as if 1–10% of tumor cell nuclei are immunoreactive for ER and suggest that similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of ER-positive BC.